Fusion biopsy industry is projected to witness a CAGR of 9.9% during the period 2025-2034. This growth can be attributed to ...

IRVINE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of innovative diagnostic solutions, is proud to announce that its Fortel ® Prostate Specific Antigen ...

With a rise in climate-related disasters — from hurricanes and storms to the recent wildfires in Los Angeles — one thing is clear: Safety is no longer limited to living in a crime-free ...

IRVINE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of innovative diagnostic solutions, is proud to announce that its Fortel® Prostate Specific ...

(Nasdaq: BMRA), a global provider of innovative diagnostic solutions, is proud to announce that its Fortel® Prostate Specific Antigen (PSA) Screening Test has received approval from the United ...

10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer - Prostate Cancer: The Second Most Common Cancer in Men Globally IRVINE ...

First author Dr Jeff Francis, Senior Scientific Officer in the Development and Cancer Group in the Division of Cancer Biology at the ICR, said: “This study gave us the chance to investigate the early ...

15, 2025 – Prostate cancer is quite common – over ... “given that our experience tells us that low-risk people probably have more harm than benefit.” Leapman agrees.